Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago.
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
SRPT Stock Surges on Promising Early Results From siRNA Programs
Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Sarepta Therapeutics' experimental siRNA therapies show promising early results
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early clinical results from two of its investigational siRNA therapies for neuromuscular diseases, showing dose-dependent muscle exposure and favorable tolerability. Phase 1/2 studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated that the αvβ6 integrin-targeted delivery platform achieved high concentrations in muscle tissue without dose-limiting toxicity.
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscular diseases with no currently approved treatments.
